Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 71.3% in October

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 295,000 shares, a growth of 71.3% from the October 15th total of 172,200 shares. Based on an average daily trading volume, of 216,700 shares, the days-to-cover ratio is presently 1.4 days. Currently, 3.9% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Roth Mkm restated a “buy” rating and set a $14.00 price objective on shares of Immix Biopharma in a research report on Monday, August 14th.

Immix Biopharma Stock Performance

IMMX stock opened at $4.25 on Tuesday. Immix Biopharma has a 52 week low of $0.87 and a 52 week high of $4.82. The firm’s fifty day moving average is $3.36 and its 200 day moving average is $2.57. The firm has a market cap of $83.64 million, a P/E ratio of -5.31 and a beta of -0.33.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Friday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). As a group, analysts forecast that Immix Biopharma will post -0.81 EPS for the current year.

Insider Activity at Immix Biopharma

In other Immix Biopharma news, Director Carey Ng purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were bought at an average cost of $2.58 per share, for a total transaction of $25,800.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $25,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Carey Ng bought 10,000 shares of the stock in a transaction on Thursday, September 14th. The shares were acquired at an average cost of $2.58 per share, for a total transaction of $25,800.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $25,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Helen C. Adams bought 13,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was purchased at an average price of $2.96 per share, for a total transaction of $38,480.00. Following the completion of the purchase, the director now directly owns 13,000 shares in the company, valued at $38,480. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 54,000 shares of company stock worth $140,190. 55.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Immix Biopharma

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in Immix Biopharma in the 2nd quarter worth $29,000. XTX Topco Ltd purchased a new stake in shares of Immix Biopharma in the 1st quarter worth about $31,000. Susquehanna International Group LLP purchased a new stake in shares of Immix Biopharma in the 1st quarter worth about $32,000. Tocqueville Asset Management L.P. purchased a new stake in shares of Immix Biopharma in the 3rd quarter worth about $41,000. Finally, BlackRock Inc. purchased a new stake in shares of Immix Biopharma in the 2nd quarter worth about $42,000. Institutional investors own 3.97% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.